Valuation: Positron Corporation

Market Cap 6.05Cr 5.31Cr 5.01Cr 4.57Cr 8.55Cr 579.87Cr 8.61Cr 60Cr 23Cr 296.25Cr 23Cr 22Cr 952.1Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.94Cr 5.21Cr 4.92Cr 4.48Cr 8.39Cr 568.98Cr 8.45Cr 59Cr 23Cr 290.68Cr 22Cr 22Cr 934.22Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+74.47% - - 6.05Cr
+0.21%+1.40%-31.15%-2.47% 1.25TCr
-7.14%-2.36%+4.88%+6.07% 415.82Cr
-2.48%+1.37%-45.08%-60.64% 121.21Cr
-0.57%+3.04%-40.46%-43.14% 109.48Cr
+0.66%+4.43%+25.11%+98.15% 109.8Cr
-1.58%+1.70%-34.60% - 103.24Cr
-3.18%-0.52% - - 100Cr
-2.64%-4.46%+29.12%+93.38% 49Cr
+7.78%-0.75%+46.15% - 33Cr
Average -0.64%+0.43%-5.76%+15.23% 254.32Cr
Weighted average by Cap. -1.45%+0.71%-20.35%+1.35%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.63Cr 8L 58.26L 22.57L 2.88Cr 22.06L 21.58L 9.25Cr 5L 4L 4L 3L 7L 4.42Cr 7L 45.76L 17.73L 2.26Cr 17.33L 16.95L 7.26Cr
Net income -23.79L -20.88L -19.72L -17.97L -33.64L -23Cr -33.88L -2.36Cr -91.39L -12Cr -89.33L -87.39L -37Cr -1.06Cr -93.04L -87.88L -80.08L -1.5Cr -101.63Cr -1.51Cr -11Cr -4.07Cr -52Cr -3.98Cr -3.9Cr -166.86Cr
Net Debt 14.24L 12.5L 11.8L 10.76L 20.14L 14Cr 20.28L 1.41Cr 54.71L 6.97Cr 53.48L 52.32L 22Cr -11.36L -10L -9L -9L -16.06L -11Cr -16.18L -1.13Cr -43.64L -5.56Cr -42.66L -41.74L -18Cr
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-